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Relaxin peptide (RLN), which signals through the relaxin family peptide 1 (RXFP1) GPCR
receptor, has shown therapeutic effects in an acute heart failure clinical trial. We have
identified a small-molecule agonist of human RXFP1, ML290; however, it does not
activate the mouse receptor. To find a suitable animal model for ML290 testing and to
gain mechanistic insights into the interaction of various ligands with RXFP1, we have
cloned rhesus macaque, pig, rabbit, and guinea pig RXFP1s and analyzed their activation
by RLN and ML290. HEK293T cells expressing macaque or pig RXFP1 responded to
relaxin and ML290 treatment as measured by an increase of cAMP production. Guinea
pig RXFP1 responded to relaxin but had very low response to ML290 treatment only
at highest concentrations used. The rabbit RXFP1 amino acid sequence was the most
divergent, with a number of unique substitutions within the ectodomain and the seven-
transmembrane domain (7TM). Two splice variants of rabbit RXFP1 derived through
alternative splicing of the fourth exon were identified. In contrast to the other species,
rabbit RXFP1s were activated by ML290, but not with human, pig, mouse, or rabbit
RLNs. Using FLAG-tagged constructs, we have shown that both rabbit RXFP1 variants
are expressed on the cell surface. No binding of human Eu-labeled RLN to rabbit RXFP1
was detected, suggesting that in this species, RXFP1 might be non-functional. We used
chimeric rabbit–human and guinea pig–human constructs to identify regions important
for RLN or ML290 receptor activation. Chimeras with the human ectodomain and rabbit
7TM domain were activated by RLN, whereas substitution of part of the guinea pig 7TM
domain with the human sequence only partially restored ML290 activation, confirming the
allosteric mode of action for the two ligands. Our data demonstrate that macaque and
pig models can be used for ML290 testing.
Keywords: relaxin, G protein-coupled receptor, RXFP1, receptor structure–function, small-molecule allosteric
agonist
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Introduction
The relaxin hormone was discovered by Dr. Frederick Hisaw
90 years ago in experiments involving the injection of serum
from pregnant guinea pigs or rabbits into virgin guinea pigs
that resulted in the softening of the pubic ligament (1). Further
experiments led to the identification of the peptide responsible for
this effect. It was the first peptide hormone identified inmammals.
The relaxin gene, RLN1, has a relatively simple structure, contain-
ing only two exons (2). The mRNA encodes the preprohormone,
which is processed by convertases to the mature 6 kDa hormone
with A- and B-chains connected to each other by two disulfide
bonds. An additional disulfide bond is located within the A-chain.
Relaxin (RLN) peptides from various mammalian species show
significant variations in amino acid sequence; however, almost
all maintain the conserved functional RXXXRXXI/V motif in the
B-chain. The analysis of the full genome sequences revealed the
presence of only one RLN gene in various species. One exception
is primates, where two RLN1 and RLN2 genes coding for almost
identical peptides are located next to each other, most likely the
result of genomic DNA duplication. It is believed that the RLN2
gene is the functional copy, as only the RLN2 peptide was isolated
from the peripheral blood (1).
The cognate receptor for RLN peptide is the G protein-
coupled receptor Relaxin Family Peptide Receptor 1, or RXFP1
(3). All RXFP1 genes cloned to date from various mammalian
species have the same conserved 18-exon genomic organization
and encode proteins with very similar structures. RXFP1 con-
tains a large extracellular ectodomain, which is unique among G
protein-coupled receptors. This domain consists of a single low-
density lipoprotein receptor type Amodule (LDLa) followed by 10
leucine-rich repeats (LRRs). The classical seven-transmembrane
(7TM) region of the RXFP1 is well-conserved among different
species. Structural studies of RLN and RXFP1 binding and activa-
tion have revealed a complexmechanismof their interaction (2). It
was established that primary high-affinity binding of RLN occurs
within the LRRs, while the secondary low-affinity interaction
occurs via the second extracellular loop (ECL) of the 7TM region.
The LDLa domain is not necessary for binding but is essential for
activation of the receptor signaling, although the detailed mecha-
nism of these interactions is still under investigation.When trans-
fected into HEK293T, CHO, or other cells, human, mouse, and rat
RXFP1s respond to RLN treatment by increasing cAMP produc-
tion. Increased phosphorylation of extracellular signal-regulated
kinase 1/2 (ERK1/2), MAPK, tyrosine kinase(s) and activation
of nitric oxide (NO) signaling in various RXFP1-transfected cells
and cells endogenously expressing RXFP1were also found (2).
Non-reproductive functions of this hormone/receptor pair
were identified through analysis of Rln1- and Rxfp1-deficient
transgenic mice, experiments with RLN injection into rodents,
and inactivation of RLN signaling using antibodies or peptide
antagonists (1, 2). It was shown that RLN behaves as an antifi-
brotic, antiapoptotic, vasodilatory, and angiogenic factor. This led
to the investigation of the therapeutic potential for RLN in several
diseases. The most advanced clinical trial to date tested the use
of recombinant RLN as a treatment for acute heart failure. The
reported analysis suggests that the treatment is well tolerated by
patients, safe, and most importantly, results in a reduced 180-day
mortality (4).
As with other peptide-based pharmaceuticals, the use of such
drugs in chronic conditions is complicated due to their short half-
life and the need for intravenous administration. An additional
disadvantage is the cost of recombinant peptide production. To
overcome these limitations, we have initiated the search for a
small-molecule agonist of RXFP1. High throughput screening of
a small-molecule library and the subsequent structure activity
campaign resulted in the identification of the first series of RXFP1
agonists with preferred biochemical and in vivo pharmacokinetic
properties, which supported further therapeutic investigation of
RLN biology (5, 6). Surprisingly, these compounds, including lead
compound, ML290, did not activate the mouse RXFP1 recep-
tor. Using chimeric human–mouse RXFP1 variants and point
mutations, we have established that amino acid differences in
the third ECL of 7TM are responsible for such specificity (5).
This mouse variant is also present in rat and hamster RXFP1s.
An overwhelming majority of the preclinical animal testing for
RLN treatment includes rodent models, and thus the inability
of small-molecule agonists to activate the mouse receptor ham-
pers preclinical studies. To find suitable in vitro and in vivo
models, we have cloned and tested in a functional cAMP assay
RXFP1 receptors from four mammalian species: rhesus macaque
(Macaca mullata), pig (Sus scrofa), European rabbit (Oryctolagus
cuniculus), and the guinea pig (Cavia porcellus). We also tested
various chimeric human constructs that had their extracellular
or 7TM parts swapped for corresponding guinea pig and rabbit
fragments to establish regions responsible for RLN and ML290
activation. For rabbit RXFP1s, which were non-responsive to
RLN, we tested surface expression, RLN binding, and activa-
tion by RLN peptides from various species. We have concluded
that pig and macaque models are suitable for ML290 testing,
whereas rodent RXFP1 genes have to be humanized for preclinical
studies.
Materials and Methods
Sequence Analysis
Genomic sequences of the RXFP1 genes for different species were
obtained from the Ensembl database1. The full-length human
and mouse RXFP1 cDNA were used to identify exons using the
Blast2seq program (7) available from the NCBI website2. Mul-
tiple sequence alignments and evolutionary tree rendering were
performed using the MUSCLE algorithm (8) at the EMBL-EBI
website3.
Production of RXFP1 Expression Constructs
From Various Species and Human–Guinea Pig or
Rabbit Chimeric RXFP1s
The human, mouse, macaque, and pig RXFP1 cDNA constructs
in baculovirus BacMam mammalian expression vector (Invit-
rogen, Carlsbad, CA, USA) were synthesized at the Eukaryotic
1http://www.ensembl.org
2www.ncbi.nlm.nih.gov
3http://www.ebi.ac.uk/Tools/msa/
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Expression Group-Protein Expression laboratory (NCI, Freder-
ick, MD, USA). The PCR primers for RT-PCR were designed
to cover the full-length sequence of the open reading frame
(ORF). PCR amplifications were performed with PfuUltra High-
Fidelity DNA polymerase (Agilent Technologies, Santa Clara,
CA, USA). Guinea pig RXFP1 (G-RXFP1) was amplified from
guinea pig ovarian cDNA (Zyagen, San Diego, CA, USA). Rab-
bit RXFP1 (R1-RXFP1 and R2-RXFP1) cDNAs were amplified
from rabbit uterus cDNA (Zyagen). All cloning was performed
using the In-Fusion® HD Cloning Kit (Clontech Laboratories,
Mountain View, CA, USA). Rabbit and guinea pig RXFP1s were
cloned into pCR3.1 mammalian expression vector (Invitrogen).
In order to study RXFP1 surface expression, rabbit cDNAs
were cloned into pcDNA3.1™/Zeo+mammalian expression vec-
tor (Invitrogen), which contained an N-terminal FLAG-tag and
a bovine prolactin signal sequence (3). It was shown previ-
ously that such additions do not alter receptor activity (14). To
make chimeric clones, the human, guinea pig, and rabbit plas-
mid were used as templates to produce PCR amplicons, which
were then used for overlapping PCR and subsequent cloning
with the In-Fusion kit. The chimeric guinea pig/human GH-
RXFP1 construct contains guinea pig RXFP1 cDNA (G-RXFP1,
1–1499 bp) encoding the ectodomain, TM1, TM2, and part of
TM3 (amino acids 1–499 of G-RXFP1), and human RXFP1
(hRXFP1, 1509–2274 bp) encoding TM3 to the C-terminal tail
of the receptor (amino acids 503–757 of hRXFP1) (Figure 1A).
The recombinant chimeric human–rabbit HR-RXFP1 was made
with the 50-part of the hRXFP1 sequence (1–972 bp, LDLa-LRR9,
1–324 aa), with the remainder being the rabbit RXFP1 sequence
(973–2277 bp, LRR9-C-terminal tail, 325–759 aa) (Figure 1A).
The recombinant chimeric rabbit–human R1H-RXFP1 or R2H-
RXFP1 contains theN-terminal rabbit RXFP1 sequence (1–972 bp
for R1-RXFP1 or 975 bp for R2-RXFP1), with the remaining
sequence being hRXFP1 (973–2274) (Figure 1A). R1- and R2-
RXFP1 denote two variants of rabbit RXFP1 cDNA. All numbers
correspond to the full-length cDNAs with the first nucleotide of
the ORF.
The rabbit RLN gene SQ10 (9) was synthesized and cloned into
pCR2.1-TOPO (Invitrogen) by Eurofins MWGOperon LLC. The
SQ10 cDNA was PCR amplified and cloned using In-Fusion kit
into a pCR3.1 vector.
At least three independent plasmids were obtained in each
cloning experiment. The cDNA inserts were fully sequenced using
overlapping primers by Eurofins MWG Operon LLC (Huntsville,
AL, USA). GenBank accession numbers are KT149378 (guinea
pig RXFP1), KT149379 (rabbit variant 1 RXFP1), and KT149380
(rabbit variant 2 RXFP1).
Relaxin Peptides and Cell Lines
Porcine relaxin peptide (10) was a gift from Dr. O. David
Sherwood (University of Illinois at Urbana-Champaign). Human
recombinant RLN peptide was obtained from PeproTech Inc.
(Rocky Hill, NJ, USA) or from Corthera (San Carlos, CA,
USA). Chemically synthesized mouse RLN peptide was a gift
from Prof. John D. Wade (Florey Institute of Neuroscience
and Mental Health, Melbourne, VIC, Australia). Human embry-
onic kidney HEK293T cells (ATCC #CRL-1573; American
Type Tissue Culture Collection, Manassas, VA, USA) used for
transfection experiments were maintained in 37°C, 5% CO2 in
Dulbecco’s Modified Eagle medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 1% -glutamine, and 1% peni-
cillin/streptomycin.
CRE-Luc BacMam Luciferase Assay
GloResponse™ CRE-luc2P HEK293T cells stably transfected with
cAMP response element-driven luciferase (CRE-Luc) reporter
(Promega, Madison, WI, USA) were transduced with human,
macaque, pig, and mouse RXFP1 expression BacMam vectors
according to the manufacturer’s protocol (Invitrogen) and incu-
bated at room temperature for 2 h in the darkwith occasionalmix-
ing. The volume of the cell culture was adjusted to 1000 cells/µl
with DMEM+ 10% FBS. Cells (3µl, 3000 cells) were plated on
1536-well white solid-bottom TC plates and incubated overnight
at 37C°, 5% CO2. Four hundred micromoles Ro 20-1724 (Sigma-
Aldrich, St. Louis, MO, USA) in PBS (1µl) was added in each
well. The cells were treated with serial dilutions of either Forskolin
(Sigma-Aldrich), ML290 (5) or porcine RLN at final concen-
trations’ range (57µM–3.5 pM) for Forskolin and ML290, and
(8.7µM–1.8 pM, or 57 ng/µl–0.012 pg/µl] for RLN. After 2 h
stimulation at 37°C, 4µl of detection reagent from Amplite™
Luciferase reporter gene assay kit (AAT Bioquest, Sunnyvale, CA,
USA) was added as a mix of 90% Component A, 5% Compo-
nent C, and 5% Component D, and incubated at room temper-
ature for 5min. Luminescent signal was measured on Viewlux
uHTS Microplate Imager (PerkinElmer, Santa Clara, CA, USA).
The data were processed using GraphPad Software (San Diego,
CA, USA).
Cell Transfection and cAMP Assays
HEK293T cell transient transfections were performed using Lipo-
fectamine 2000 transfection reagent (Life Technologies, Grand
Island, NY, USA) according to the manufacturer’s instructions.
Cells transiently expressing the RXFP1 receptors were usedwithin
48 h of transfection. Each construct was tested at least three
times. For cell-conditioned media stimulation, HEK293T cells
were transfected with the rabbit RLN construct (SQ10) or an
empty pCR3.1 vector, and cells were cultured for 24 h. The media
was used to stimulate HEK293T cells transfected with the RXFP1
receptors.
Directmeasurement of cAMPproductionwas performed using
the HTRF cAMP HiRange kit (CisBio, Bedford, MA, USA).
HEK293T cells transiently transfected with different RXFP1
receptors were stimulated with various concentrations of RLN
peptides or ML290 for 60min at 37°C, 5% CO2, after which,
two HTRF detection reagents (diluted according to assay kit
directions in HTRF lysis buffer) were added. The plates were
incubated for 60min at room temperature, and the signal was
read on a FLUOstar Omega (BMG Labtech, Cary, NC, USA)
plate reader. cAMP levels were calculated according to the
manufacturer’s instructions against a standard curve. Statistical
processing of the data was performed using GraphPad Prism
software.
For the indirect cAMP assay, changes in cAMP signaling
were measured by co-transfection of receptors with a CRE-β-
galactosidase (CRE-β-gal) reporter construct (11). Cells were
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FIGURE 1 | Alignment of RXFP1 proteins from various species.
(Continued)
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FIGURE 1 | Continued
(A) Amino acid alignment of RXFP1 receptor sequences. The position of the
extra amino acid (V98) in rabbit receptor variant R2 is shown above the
sequence with an arrow. Functional domains are shown below the sequences.
LDLa is low-density lipoprotein class A domain; LRR is leucine-rich repeat,
TM1–7 are transmembrane domains; ICL1–3 are intracellular loops of
seven-transmembrane domain; ECL1–3 are extracellular loops of
seven-transmembrane domain. The highlighted brown box is the third
extracellular loop and adjacent amino acids required for ML290 activation of
RXFP1. Amino acids conserved in all seven species are in red; amino acids
specific for the rabbit sequence are highlighted in yellow. The vertical line at
position 324 indicates the fusion site in chimeric rabbit/human receptor
(RH-RXFP1). The vertical line at position 502 indicates the fusion site in chimeric
guinea pig/human receptor (GH-RXFP1). (B) Evolutionary tree showing the
relationship of various RXFP1 proteins. The rabbit sequence is the most
diverged.
stimulated for 6 h at 37°C with RLN peptides or ML290 at various
concentrations. A non-linear regression sigmoidal dose–response
curve was then produced using GraphPad Prism. All experiments
were conducted at least three times with three to four replicates
each time.
Cell Total and Surface Expression Assay of
RXFP1
HEK293T cells were transfected with RXFP1 plasmid DNA or
empty vector pCR3.1 as described above. After 24 h incubation
at 37°C, cells were harvested in PBS/5mM EDTA. To deter-
mine surface expression, 0.5 106 cells were fixed in stain buffer
(2% BSA/PBS) containing 3.7% formaldehyde, washed, and incu-
bated with 0.5µg anti-FLAG M1 Ab (Sigma) for 30min at 4°C.
After washing, the cells were then incubated with 1µg Alexa
Fluor 488 goat anti-mouse IgG (Life Technologies) for 20min
at 4°C. Cells were washed and resuspended in stain buffer for
analysis on an Accuri C6 flow cytometer (BD Biosciences, San
Jose, CA, USA). For total expression, 0.2% Tween-20 (Bio-Rad)
was added to the stain buffer at all steps and the cells were
processed identically. Cells transfected with empty vector were
used as the negative cut-off to determine RXFP1 expression. All
experiments were repeated three times in triplicates. Differences
in receptor expression were quantified as the ratios of surface
expression to total expression, and analyzed with a one-way
ANOVA.
Ligand-Binding Assays
Saturation-binding studies using Eu-labeled humanH2 RLN (Eu-
H2 RLN) were performed on whole cells as described previously
(12). Cells stably expressing RXFP1 (13) or with a semi-stable
transfection of R1-RXFP1 selected using FACS (14) were used
in this experiment. Increasing concentrations of Eu-H2 RLN
(0.1–50 nM) were utilized and non-specific binding was deter-
mined in presence of 1µM of unlabeled H2 RLN. Readings were
taken in triplicate and read on a BMG PolarStar plate reader
in clear-bottomed, opaque-walled 96-well plates (PerkinElmer).
All experiments were repeated three times. Data were ana-
lyzed using GraphPad PRISM and presented as the mean per-
centage specific binding SEM of independent experiments. A
non-linear regression one-site binding curve was then fitted
and resulting pKd, and Bmax values were subjected to one-
way ANOVA and uncorrected Fisher’s LSD comparison test.
In this experiment, the cell total and surface expression was
analyzed using a previously described method (15). Differ-
ences in receptors expression were assessed using a Student’s
t-test.
Results
RXFP1 Genes
The ENSEMBL sequence of rhesus macaque RXFP1 (RXFP1-
202 ENSMMUT00000041571) had high homology to the human
RXFP1 sequence at both the mRNA and amino acid level. The
18-exon structure encoded 757 amino acids with 99% identity to
the human protein after removing 22 extra amino acids at the N-
terminus (Figure 1). Of the 10 substitutions identified, two were
located in the N-terminal signal peptide. The LDLa and LRRs
were identical between the two species, as well as ECL3, which
is important for the ML290 response. Analysis of the pig RXFP1
annotated sequence revealed the absence of the first exon, but
three additional 50 small exons with no homology to the human or
mouse sequence. Using human exon 1 as a probe, we performed
a BLAST search of the 50 kb pig genomic sequence upstream of
the putative RXFP1 exon 2. The search revealed exon 1 of pig
RXFP1, separated from exon 2 by a 42 kb intron, a size comparable
to hRXFP1 intron 1. All intron–exon boundaries contained con-
served GT and AG sequences at the 50- and 30-ends of the introns,
which are required for proper RNA splicing. Alignment of the
resulting full-length 2277 bp sequence with human cDNA showed
91% identity. The pig RXFP1 758 aa protein sequence was 92%
identical to the human sequence (Figure 1A). The second valine
in the TM6 domain, adjacent to ECL3, was substituted for leucine
in the pig sequence (V L/V K F L S L L Q V E I P G T). As both
macaque and pig cDNAs showed high homology to the human
sequence, we chemically synthesized corresponding cDNAs and
cloned them into a BacMam vector. Mouse and human cDNA
expression BacMam vectors were also produced.
Analysis of the guinea pig annotated RXFP1 genomic sequence
and cDNA sequences identified 17 exons with high homology to
the corresponding human exons. A BLAST search of the upstream
genomic sequence revealed that exon 1 was separated from exon
2 by a 42.8 kb intron. The putative full-length G-RXFP1 cDNA
was 2268 bp long, encoding a 755 aa protein. At the amino acid
level, the guinea pig RXFP1 sequence was 84 and 80% identical to
the human and mouse RXFP1 proteins, respectively (Figure 1A).
The ECL3 sequence was identical to the pig sequence. Since
the guinea pig sequence was more divergent from the human
and mouse sequences, we used RT-PCR with primers designed
from the established first and last exons to generate full-length
cDNA. The RT-PCR fragments were obtained from total ovarian
guinea pig RNA. Comparison of the sequenced cDNA clones
with the genomic sequence from GenBank identified only one
synonymous substitution.
Next, we analyzed rabbit genomic DNA. Both the cDNA and
predicted protein sequence of rabbit RXFP1 were quite different
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from the human and mouse sequences, with the 30 exons not well
defined. We used RT-PCR with primers designed from the first
and the last exons and total uterine rabbit RNA to obtain the
expected 2.3 kb full-length sequence of R-RXFP1. The fragments
were cloned into pCR3.1 vector, and sequencing of the resultant
cDNA clones revealed two variants differing by 3 bp in the 50end
(Figure 2). Comparison with the genomic sequence suggested
that the variant with the additional TAG sequence was a result of
alternative splicing at the 50-end of exon 4. We performed direct
sequencing of the RT-PCR products to confirm the presence of
both variants in total mRNA. As shown in Figure 2, the chro-
matogram depicts a single sequence at the end of exon 3, followed
by two overlapping sequences present at equal ratios, as evident
by the heights of the overlapping nucleotide picks. Alignment with
the genomic sequence showed that the 2277 bp (or 2280 bp) cDNA
was encoded by the 18 exons as in other species. When com-
pared to GenBank genomic sequence, all putative exon–intron
boundaries, with the exception of the beginning of exon 4, were
conserved in rabbit cDNAs. Four synonymous differences were
found in our cDNA versus GenBank genomic sequence. At the
amino acid level, rabbit RXFP1 sequence was 84 and 79% identical
to human and mouse proteins, respectively. The ECL3 sequence
was identical to the pig sequence (Figure 1A).
Multiple sequence analysis showed the primate and rodent
RXFP1s grouped together, with the pig RXFP1 sequence situated
between them (Figure 1B). Rabbit RXFP1 was the most diverged.
In rabbit RXFP1, there were multiple substitutions in amino acid
positions conserved among the other species, including in the
extracellular, 7TM, and C-terminal part (Figure 1A).
Macaque and Pig RXFP1 Receptors Respond to
RLN and ML290 in a CRE-Reporter cAMP Assay
To analyze the functional activity of the synthesized macaque
and pig RXFP1s, we used a CRE-Luc BacMam luciferase assay
(Figure 3). Human and mouse RXFP1s were used in these exper-
iments as controls. The cells were stimulated for 2 h, and the ele-
vation of cAMP production was detected by increased luciferase
FIGURE 2 | Alternative splicing of the intron 3 and exon 4 in rabbit
RXFP1 genomic DNA. The upper sequence shows the intron (green) and
exon (black) boundaries in the genomic DNA. Three additional nucleotides (in
red) are added to the mRNA as result of alternative splicing, as shown with
the red line. Below is the sequencing chromatogram showing the presence of
two sequences after the alternative splicing site. Note an equal size of the
peaks in the overlapping sequence, indicating an equal representation of the
two variants in the total mRNA pool.
activity. All four receptors showed similar EC50when treated with
porcine RLN (Figure 3A). Human,macaque, and pig RXFP1s also
responded strongly to ML290 stimulation (Figure 3B; Table 1).
Previously, we did not see an increase of cAMP in cells transfected
with the mouse receptor in a direct cAMPHTRF assay (5). In this
experiment, there was significant increase in luciferase activity in
cells expressing mouse RXFP1 receptor in response to the highest
concentrations of ML290.
Characterization of Guinea Pig RXFP1
G-RXFP1 response to RLN and ML290 treatment was tested
by measuring cAMP production in HEK293T cells transiently
transfected with receptor. A direct HTRF assay to measure cAMP
concentrationwas used in these experiments, and cells transfected
FIGURE 3 | Activation of macaque and pig RXFP1 receptors by RLN
and ML290. (A) Porcine RLN-induced cAMP response. (B) ML290-induced
cAMP response. HEK293T cells with CRE-luc reporter were transduced with
BacMam RXFP1 expression vectors. RLU, relative luciferase units. Data are
expressed as meanSEM.
TABLE 1 | Activation of RXFP1 receptors with relaxin and ML290.
Ligand RLN ML290
Receptor
Human *** ***
Macaque *** ***
Pig *** ***
Guinea pig *** No
Guinea pig/human *** *
Rabbit 1 and 2 No **
Human/rabbit ** **
Rabbit 1(2)/human No **
Mouse *** No
*Weak, **intermediate, ***strong activation of the receptor.
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with hRXFP1 were used as a control. As shown in Figure 4,
G-RXFP1 responded to porcine RLN, although the maximum
response was lower than that of hRXFP1. There was small
response to ML290 only at highest concentration of compound
used. A chimeric guinea pig receptor containing the TM3-C-
terminal end of human RXFP1 was created (Figure 1); analy-
sis of cAMP production in cells transfected with the chimeric
receptor GH-RXFP1 showed ML290 responsiveness, albeit to
a much lower level than in hRXFP1 (p< 0.001) (Figure 4;
Table 1).
Characterization of Rabbit RXFP1
Two variants of rabbit RXFP1 cDNA with and without the addi-
tional amino acid in the LDLa-LRRs linker (R1-RXFP1 and R2-
RXFP1, respectively) were used in a transient transfection of
HEK293T cells, and the cAMP response to ligand treatment was
measured. Both failed to respond to porcine RLN, but generated
an increase in cAMP after stimulation with ML290 (data not
shown). One explanation for the lack of receptor activation could
be poor expression of the rabbit receptors on the cell membrane.
To test for cell surface expression, we used modified R1- and
R2-constructs with a FLAG-tag at the N-terminal part of the
FIGURE 4 | Activation of guinea pig and guinea pig–human chimeric
receptors by RLN and ML290. (A) Porcine RLN-induced cAMP response.
(B) ML290-induced cAMP response. HEK293T cells were transiently
transfected with RXFP1 expression vectors and cAMP was determined using
HTRF cAMP assay. cAMP activity is expressed as the percentage of 10µM
Forskolin-stimulated response. Data are expressed as meanSEM, each
point represent triplicate measurements. The experiment was repeated three
times. *p<0.05, **p<0.01, ***p<0.001 compared to hRXFP1.
receptor. Both receptors were expressed at the same or greater
levels relative to a FLAG-tagged human RXFP1 (Figure 5). The
HTRF assay on FLAG-tagged rabbit receptors failed to detect
cAMP production when they were stimulated by porcine RLN.
Stimulation withML290 produced a cAMP increase in cells trans-
fected with both rabbit receptors, albeit with lesser efficacy than
hRXFP1 (Figure 6).
Two chimeric constructs were created to identify the region of
the rabbit receptor responsible for its lack of RLN response: R1H-
RXFP1 and R2H-RXFP1, which contain most of the ectodomain
of the two rabbit receptors and the 7TM domain of hRXFP1; and
HR-RXFP1, which contains most of the hRXFP1 ectodomain and
rabbit 7TM (Figure 1). The N-terminus contains LRR4, 5, 6, and
8, which have been identified as the sites of RLN binding (2). As
shown in Figure 6A, R1H-and R2H-RXFP1 were inactive when
stimulated with porcine RLN, whereas HR-RXFP1 responded at
a low level to RLN stimulation. While all three receptors respond
to ML290, the level of activation of R1H- and R2H-RXFP1 was
higher than that of R1-, R2-, or HR-RXFP1-transfected cells
(Figure 6B; Table 1).
In addition to porcine RLN, we analyzed the response of the
two rabbit RXFP1 variants to human andmouse RLN in theHTRF
cAMP assay (Figure 7A). In all cases, 10 nM of peptide failed to
stimulate cAMP production in cells transiently transfected with
rabbit receptors, whereas they responded to 5µM of ML290.
Human receptor was active with all ligands.
To test the activity of rabbit receptor versus rabbit RLN (SQ10),
we designed an expression construct of the latter gene. HEK293T
cells were transfected with SQ10, and conditioned medium was
used for activation of cells expressing rabbit, human, and guinea
pig RXFP1s. Cells transfected with the latter two receptors
responded to SQ10 treatment with cAMP production measured
by the HTRF assay (Figure 7B). No response was recorded from
cells transfected with R1- or R2-RXFP1, suggesting that rab-
bit RLN does not induce cAMP production through RXFP1 in
rabbits.
FIGURE 5 | Expression of two rabbit RXFP1 receptors compared to
human RXFP1. Shown is the total and cell surface RXFP1 expression in
transiently transfected HEK293T cells. Data are expressed as meanSEM,
each point represent triplicate measurements. The experiment was repeated
three times. *p<0.05 compared to hRXFP1.
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FIGURE 6 | Activation of rabbit and rabbit–human chimeric receptors by
RLN and ML290. (A) Porcine RLN-induced cAMP response.
(B) ML290-induced cAMP response. HEK293T cells were transiently
transfected with RXFP1 expression vectors and cAMP was determined using
the HTRF cAMP assay. cAMP activity is expressed as the percentage of
hRXFP1 cAMP activation by 10 nM of RLN. Data are expressed as
meanSEM; each point represents triplicate measurements. The experiment
was repeated at least three times. ***p<0.001 compared to hRXFP1.
Binding of Eu-human RLN to the rabbit R1-RXFP1 recep-
tor was evaluated in a saturation binding assay using selected
HEK293T cells with a high level of RXFP1 (Figure 8). The R1-
RXFP1 was well-expressed on the cell surface membrane, with an
even somewhat higher level than hRXFP1 (Figure 8A), similar
to what was detected in transiently transfected cells. These cells
were used in human RLN-binding experiments. While strong
binding of labeled RLN was detected with human RXFP1, no
binding to rabbit R1-RXFP1 receptor was found (Figure 8B). In
the CRE-reporter-based cAMP assay, hRXFP1 and R1-RXFP1
were stimulated with human RLN and ML290. For ML290
treatment, the cAMP response in cells transfected with rab-
bit receptor measured using this approach was comparable to
hRXFP1. At very high concentrations of RLN (>1µM), there was
some increase in β-gal activity for R1-RXFP1-transfected cells
(Figures 8C,D).
Discussion
Due to its vasodilatory, antifibrotic, and cytoprotective properties,
among others, RLN hormone induces pleotropic responses in
multiple normal and diseased tissues and organs (2). In animal
models, treatment with RLN has shown therapeutic effects in
induced liver, pulmonary, kidney, and heart fibrosis, as well as
diabetes, ischemia–perfusion injury, wound healing, and other
common diseases. Most of these studies were performed with
rodents, although other species were used to a lesser degree.
However, there are noted differences in the physiology of this
hormone in other species; for instance, the concentration of RLN
during pregnancy in mice is 100 times higher than in women
(1). The largest clinical trial of the therapeutic use of RLN was
in acute heart failure patients (4). The data indicated the possible
benefits of even short-term intravenous RLN administration. We
have recently reported the discovery of the first small-molecule
agonist series for the RLN receptor (5, 6). This has raised the
possibility of developing a therapeutic agent with high stability,
activity, specificity, and potentially oral delivery. However, we
have shown that the identified compounds did not activate the
mouse RLN receptor. Using chimeric human–mouse receptors
and site-specific mutagenesis, we have determined that the amino
acid sequence of the ECL3 of the 7TM determines the recep-
tor selectivity. The mutation of four amino acids in the mouse
receptor ECL3 made it responsive to small agonist treatment.
Analysis of the available sequences in GenBank revealed that
both rat and hamster RXFP1s have the mouse variant of ECL3,
and thus these rodents could not be used for the analysis of
small molecules. Here, we have cloned and tested the functional
activation of RXFP1s from mammals of four different orders,
Primates (rhesus macaque), Artodactyla (pig), Lagomorpha (rab-
bit), and Rodentia (guinea pig). The data show that the RXFP1
receptors from the first two species are fully activated by RLN
and ML290 and hence, the corresponding animal models can
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FIGURE 7 | Activation of rabbit receptors by relaxin peptides from
different species. (A) Activation of two rabbit receptor variants (R1- and
R2-RXFP1) and hRXFP1with 10 nM of human (hRLN), mouse (mRLN), and
porcine (pRLN) relaxin peptides, and by 5µM of ML290. Treatments of rabbit
RXFP1 are statistically significant compared to hRXFP1, ***p<0.001.
(B) Activation of rabbit (R1-), human (h), and guinea pig (G-) RXFP1s with
rabbit relaxin SQ10. Conditioned media from HEK293T cells transfected with
SQ10 and control empty vector was used for cell stimulation. cAMP activity is
expressed as the percentage of 10µM Forskolin stimulation for each type of
cells. Data are expressed as meanSEM; each point represents triplicate
measurements. The experiment was repeated at least three times. Treatment
of R1-RXFP1 is statistically significant (p<0.0001) compared to hRXFP1 or
G-RXFP1.
be used for RLN and ML290 studies. Guinea pig RXFP1 does
not respond to ML290. The use of rabbit in studies of RLN
biology should be further critically assessed as in our experiments
RLN did not bind to the rabbit RXFP1 receptors nor did it acti-
vate cAMP response at physiologically relevant concentrations
(Table 1).
The availability of genome sequencing data allows quick
retrieval of gene information. However, a critical appraisal of
this information is required. In the case of RXFP1, the genomic
structure of cloned human, mouse, and rat receptors is well-
established and each comprises 18 coding exons (16). The same
conserved structure was annotated for macaque and pig genes. In
the case of guinea pig and rabbit, we identified the missing first
exon using a BLAST search of the genomic DNA. The correct
assembly of the ORFs was further confirmed by RT-PCR isolation
of the full-length cDNAs, cloning, and sequencing. We found
two splice variants of the rabbit receptor mRNA, an apparent
consequence of a mutation in the splice site of the intron 3/exon 4
boundary, which results in one extra amino acid in the LDL–LRR
linker. While splice variants of hRXFP1 affecting full exons were
described (13, 17, 18), such additional insertion of only three
nucleotides is unique for rabbit RXFP1.
Comparison of the various sequences indicated that pig, rabbit,
and guinea pig receptors share the same ECL3 sequence, differing
from the human and monkey sequence by only one amino acid
(V647). Multiple substitutions were found in the rabbit sequence,
including three unique substitutions in the LDLa domain, numer-
ous changes in the LDLa–LRR linker (17 unique amino acids)
and in several LRR repeats. Notably, all previously identified
amino acids essential for the structural and functional integrity of
human RXFP1 remained conserved in the rabbit receptor: amino
acids required for the coordination of Ca2+ binding and receptor
activation in the LDLa domain (19, 20), previously described
LRR amino acids important for primary RLN binding by the
RXFP1 ectodomain (2), and the sites crucial for secondary binding
of RLN peptide to the ECL1 or ECL2 (21). However, there is
a substitution of serine at amino acid 33, which is proline in
all the other RXFP1 receptors. This residue is located next to
one of the crucial cysteine residues in the LDLa module that
are essential for its function. It is possible that this substitution
results in a structural perturbation in the LDLamodule. Addition-
ally, there are numerous proline substitutions in the LDLa–LRR
linker region which would result in structural changes in this
domain. Recent studies have suggested that this linker region
may have an important role in receptor activation by the LDLa
module (14).
Analysis of RLN response measured by cAMP production
revealed RLN activity in all but the rabbit receptor. Neither of the
two rabbit RXFP1 variants responded to stimulation with RLN
peptides from various mammalian species, including previously
described rabbit RLN homolog SQ10 (22). Moreover, we were
not able to detect binding of labeled human recombinant RLN
to the rabbit receptor. Taken together, the homology of the iso-
lated rabbit clones with other species RXFP1s, almost identical
sequence of our cDNAs to the GenBank genomic DNA, and
identity of the cloned cDNA with the DNA obtained by direct
sequencing of the isolated RT-PCR fragments all suggest that
we have isolated the correct full-length rabbit RXFP1 clones.
The rabbit receptors were activated by ML290, indicating their
functionality.
It was recently suggested that there are five copies of the RLN
gene in the rabbit genome, which raises the question of whether
the rabbit RLN peptide used in our experiments is correct (23).
Putative translation of two rabbit RLN genes produced identical
peptides. The three other RLN genes encoding putative rabbit
RLN peptides each differ from the first two by a single evolu-
tionary non-conserved amino acid (23). The sequence of the first
peptide was also identical to the previously reported sequence
encoded by SQ10 cDNA obtained by RT-PCR (9) and partial pro-
tein sequencing (24). Therefore, we decided to use SQ10 cDNA in
our experiments to generate rabbit RLN. Importantly, it activated
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FIGURE 8 | Rabbit RXFP1 does not bind relaxin peptide. (A) Total and cell
surface expression of hRXFP1 and R1-RXFP1. Expression is normalized to the
expression of human receptor. ***p<0.001 compared to hRXFP1.
(B) Saturation binding using Eu-labeled H2 RLN. (C) Human RLN-induced
cAMP response. (D) ML290-induced cAMP response. cAMP activity is
expressed as the percentage of the 5µM Forskolin-stimulated response for
each receptor. Data are expressed as meanSEM; each point represents
triplicate measurements. The experiment was repeated at least three times.
human and guinea pig receptors and thus was fully functional.
Taking into account that there is only a single amino acid dif-
ference between the SQ10 sequence and other three putative
peptides, it seems highly unlikely that the latter RLNs will activate
rabbit RXFP1.
Surprisingly, in an indirect assay, activation of a CRE-reporter
was detected when RLNwas used at a concentration far exceeding
the detected serum RLN range in rabbits (25). Similarly, activa-
tion of the CRE-reporter was observed with high-dose ML290
treatment on the mouse receptor, despite no activation being seen
in the direct HTRF cAMP assay. One explanation is that ligand
interactions with the receptor triggered signaling pathways other
than cAMP in both CRE-reporter assays, which then affected
CRE transcriptional activity (26). It was demonstrated that RLN
activated various signaling pathways in cells expressing RXFP1
(27, 28). It should be noted, however, that the fact that we were
not able to detect human RLN binding to the rabbit receptor in
our assays contradicts this suggestion.
Another possible explanation for the loss of activity of rabbit
receptors is that the activation of rabbit receptor by RLN requires
dimerization or interaction with other GPCRs or other cellular
partners. It is possible that such partners might be rabbit-specific
or that the receptor works only in rabbit cells. Such interactions
have been shown; for instance, RXFP1 can directly interact with
the angiotensin II type 2 receptor to regulate downstream cellular
signaling (29). It is also possible that rabbit RLNs do not signal
through RXFP1, and other ligands activate this receptor. In any of
these scenarios, the question of whether rabbit is an appropriate
model for RLN studies should be carefully examined. One might
wonder if treatment of rabbits rather than guinea pigs with serum
from the pregnant animals in Dr. Hisaw’s original experiments
would have led to the discovery of RLN.
The rabbit and guinea pig receptors provide new structural
templates for analysis of RLN and ML290 activation of RXFP1.
Using chimeric human and rabbit receptors, we showed here that
the extracellular part of the rabbit receptor is responsible for the
failure of RLN activation. Indeed, it was shown that primary
binding of RLN to RXFP1 involve sites within LRR4, 5, 6, and 8
(2). In contrast, the 7TM region of RXFP1, which is the site of
allosteric small-molecule agonist binding, is functional in rabbits.
The opposite was true for guinea pig RXFP1: despite having the
same ECL3 sequence as pig or rabbit RXFP1, the receptor was
activated by ML290 only at highest concentration of ML290 and
with much lower efficacy than hRXFP1. As noted above, one
potential site of ML290 interaction with the receptor is ECL3
(5). To further define the region of interaction, we substituted
the C-terminus guinea pig fragment with human sequence in
chimeric GH-RXFP1. This part contained peptide regions adja-
cent to ECL3: TM3–7, ICL2–3, and ECL2–3. The data showed
that the efficacy of ML290 stimulation was improved, however,
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it was still lower than in hRXFP1-transfected cells. Thus, spe-
cific amino acids in the guinea pig TM1–3, or their interac-
tion with TM3–7 amino acids might be responsible for ML290
binding or activation. Importantly, a modified mouse receptor
with humanized ECL3 is activated by ML290 (5). Thus, amino
acid substitutions unique for the guinea pig 7TM domain and
not present in other species might be responsible for the lack of
activation with ML290. Identification of such sites might help in
understanding the structural basis of ML290 and RXFP1 inter-
actions. Collectively, our data demonstrate that different parts of
the receptor are important for RLN- or ML290-induced activa-
tion and thus indicate the allosteric mode of activation by two
ligands.
In summary, the information derived from this study may
help in the selection of appropriate animal models to study the
biological effects of RLN andML290. The comparisons of RXFP1
sequences have provided further insights into the structural basis,
mechanism of activation, and selectivity of peptide and small-
molecule agonists for RXFP1.
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